- Investing Ideas
- Danish Pharmaceuticals & Biotech Potentially Undervalued Companies
Danish Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
6
Companies with a Value score of at least 3, ordered by Value score
6 companies
Bavarian Nordic
Market Cap: DKK 14.2b
Develops, manufactures, and supplies life-saving vaccines.
BAVA
DKK 187.60
7D
6.3%
1Y
-21.7%
H. Lundbeck
Market Cap: DKK 40.9b
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
HLUN B
DKK 43.14
7D
3.8%
1Y
11.8%
Novo Nordisk
Market Cap: DKK 1.3t
Engages in the research and development, manufacture, and distribution of pharmaceutical products.
NOVO B
DKK 292.40
7D
-4.5%
1Y
-15.9%
H. Lundbeck
Market Cap: DKK 40.9b
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
HLUN A
DKK 36.50
7D
2.1%
1Y
13.5%
Gubra
Market Cap: DKK 6.1b
A disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally.
GUBRA
DKK 375.80
7D
3.9%
1Y
4.4%
Strategic Partners
Market Cap: DKK 31.1m
Does not have significant operations.
STRAP
DKK 745.00
7D
6.4%
1Y
-27.3%